145 related articles for article (PubMed ID: 9226107)
21. Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators.
Essig M; Tartaro A; Tartaglione T; Pirovano G; Kirchin MA; Spinazzi A
Acad Radiol; 2006 Jun; 13(6):744-51. PubMed ID: 16679277
[TBL] [Abstract][Full Text] [Related]
22. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging.
Tsuda N; Okada M; Murakami T
Invest Radiol; 2007 Apr; 42(4):242-7. PubMed ID: 17351431
[TBL] [Abstract][Full Text] [Related]
23. Focal nodular hyperplasia of the liver: detection and characterization with plain and dynamic-enhanced MRI.
Mortelé KJ; Praet M; Van Vlierberghe H; de Hemptinne B; Zou K; Ros PR
Abdom Imaging; 2002; 27(6):700-7. PubMed ID: 12395259
[TBL] [Abstract][Full Text] [Related]
24. Liver I: Currently available gadolinium chelates.
Mitchell DG
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):37-51. PubMed ID: 8673715
[TBL] [Abstract][Full Text] [Related]
25. [MR imaging of liver metastasis using Gd-EOB-DTPA].
Kuwatsuru R
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1234-41. PubMed ID: 19692760
[TBL] [Abstract][Full Text] [Related]
26. MR imaging of the liver. Contrast agents.
Mahfouz AE; Hamm B
Magn Reson Imaging Clin N Am; 1997 May; 5(2):223-40. PubMed ID: 9113673
[TBL] [Abstract][Full Text] [Related]
27. [Status and development of new clinical contrast media for MR diagnosis of liver diseases].
Rummeny EJ; Peters PE
Radiologe; 1992 May; 32(5):225-31. PubMed ID: 1635982
[TBL] [Abstract][Full Text] [Related]
28. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents.
Kimura J; Ishiguchi T; Matsuda J; Ohno R; Nakamura A; Kamei S; Ohno K; Kawamura T; Murata K
Radiat Med; 2005 Aug; 23(5):322-6. PubMed ID: 16342903
[TBL] [Abstract][Full Text] [Related]
29. Future directions in magnetic resonance contrast media.
Runge VM; Gelblum DY
Top Magn Reson Imaging; 1991 Mar; 3(2):85-97. PubMed ID: 2025435
[TBL] [Abstract][Full Text] [Related]
30. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI).
Motosugi U; Ichikawa T; Sou H; Sano K; Ichikawa S; Tominaga L; Araki T
J Magn Reson Imaging; 2009 Oct; 30(4):849-54. PubMed ID: 19787734
[TBL] [Abstract][Full Text] [Related]
31. A new class of Gd-based DO3A-ethylamine-derived targeted contrast agents for MR and optical imaging.
Mishra A; Pfeuffer J; Mishra R; Engelmann J; Mishra AK; Ugurbil K; Logothetis NK
Bioconjug Chem; 2006; 17(3):773-80. PubMed ID: 16704217
[TBL] [Abstract][Full Text] [Related]
32. MultiHance: help or hype?
Bartolozzi C; Spinazzi A
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S151-9. PubMed ID: 10608411
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: an animal study.
Hsu JS; Jaw TS; Liu GC; Wang YM; Chen SH; Kuo YT; Jao JC; Li CW; Tsai KB
J Magn Reson Imaging; 2004 Oct; 20(4):632-9. PubMed ID: 15390149
[TBL] [Abstract][Full Text] [Related]
34. MR imaging of the liver using gadolinium chelates.
Low RN
Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):717-43, vi. PubMed ID: 11694435
[TBL] [Abstract][Full Text] [Related]
35. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
[TBL] [Abstract][Full Text] [Related]
36. In vitro evaluation of alternative oral contrast agents for MRI of the gastrointestinal tract.
Babos M; Schwarcz A; Randhawa MS; Marton B; Kardos L; Palkó A
Eur J Radiol; 2008 Jan; 65(1):133-9. PubMed ID: 17485189
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and characterization of poly(L-glutamic acid) gadolinium chelate: a new biodegradable MRI contrast agent.
Wen X; Jackson EF; Price RE; Kim EE; Wu Q; Wallace S; Charnsangavej C; Gelovani JG; Li C
Bioconjug Chem; 2004; 15(6):1408-15. PubMed ID: 15546209
[TBL] [Abstract][Full Text] [Related]
38. Contrast-enhanced MR angiography in rats with hepatobiliary contrast agents.
Yoshikawa K; Inoue Y; Shimada M; Akahane M; Itoh S; Seno A; Hayashi S
Magn Reson Imaging; 2004 Sep; 22(7):937-42. PubMed ID: 15288134
[TBL] [Abstract][Full Text] [Related]
39. [Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA].
Stroszczynski C; Gaffke G; Gnauck M; Streitparth F; Wieners G; Lopez-Häninnen E
Radiologe; 2004 Dec; 44(12):1185-91. PubMed ID: 15549226
[TBL] [Abstract][Full Text] [Related]
40. MR contrast agents for liver imaging: what, when, how.
Gandhi SN; Brown MA; Wong JG; Aguirre DA; Sirlin CB
Radiographics; 2006; 26(6):1621-36. PubMed ID: 17102040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
